{"id":1982,"date":"2025-03-31T13:37:10","date_gmt":"2025-03-31T11:37:10","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=1982"},"modified":"2025-03-31T14:00:03","modified_gmt":"2025-03-31T12:00:03","slug":"a-sars-cov-2-xbb-1-5-komponensu-oltoanyag-eredmenyessege-a-korhazi-ellatast-igenylo-covid19-ellen-abban-az-idoszakban-amikor-a-megbetegedesek-legnagyobb-reszet-a-ba-286-jn-1-virusvarians-okozta","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2025\/03\/31\/a-sars-cov-2-xbb-1-5-komponensu-oltoanyag-eredmenyessege-a-korhazi-ellatast-igenylo-covid19-ellen-abban-az-idoszakban-amikor-a-megbetegedesek-legnagyobb-reszet-a-ba-286-jn-1-virusvarians-okozta\/","title":{"rendered":"A SARS-CoV-2 XBB.1.5 komponens\u0171 olt\u00f3anyag eredm\u00e9nyess\u00e9ge a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 COVID19 ellen abban az id\u0151szakban, amikor a megbeteged\u00e9sek legnagyobb r\u00e9sz\u00e9t a BA.286\/JN.1 v\u00edrusvari\u00e1ns okozta"},"content":{"rendered":"

A VEBIS<\/strong>1<\/sup><\/strong> k\u00f3rh\u00e1zi vizsg\u00e1latba bevont eur\u00f3pai orsz\u00e1gok 65 \u00e9ves \u00e9s id\u0151sebb n\u00e9pess\u00e9ge k\u00f6r\u00e9ben v\u00e9gzett kutat\u00e1s eredm\u00e9nyei, <\/strong><\/span><\/p>\n

2023. november \u2013 2024. m\u00e1jus<\/strong><\/span><\/p>\n

A COVID19 elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9r\u0151l (CVE) egy 12 eur\u00f3pai orsz\u00e1g r\u00e9szv\u00e9tel\u00e9vel zajl\u00f3, multicentrikus k\u00f3rh\u00e1zi vizsg\u00e1latban (VEBIS projekt1<\/sup>) \u00a0v\u00e9gezt\u00fcnk kutat\u00e1st. A kutat\u00e1s id\u0151szak\u00e1ban (2023. november \u00e9s 2024. m\u00e1jus k\u00f6z\u00f6tt) az adapt\u00e1lt monovalens SARS-CoV-2 XBB.1.5 alvari\u00e1ns elleni olt\u00f3anyagok voltak sz\u00e9les k\u00f6rben aj\u00e1nlottak a kock\u00e1zati csoportok sz\u00e1m\u00e1ra. Ugyanebben az id\u0151szakban egy \u00faj SARS-CoV-2 alvari\u00e1ns terjedt el, a BA.2.86\/JN.1 lesz\u00e1rmaz\u00e1si vonala, amely h\u00e1tt\u00e9rbe szor\u00edtotta a kor\u00e1bban domin\u00e1ns XBB.1.5 alvari\u00e1nst.<\/p>\n

1<\/strong>. \u00e1bra: A BA.286\/JN.1 \u00e1ltal domin\u00e1ns id\u0151szakban az XBB.1.5 Covid19 elleni olt\u00f3anyagok eredm\u00e9nyess\u00e9ge a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 SARS-CoV-2 fert\u0151z\u00e9ssel szemben, 65 \u00e9ves \u00e9s id\u0151sebb popul\u00e1ci\u00f3, r\u00e9sztvev\u0151 orsz\u00e1gok – VEBIS k\u00f3rh\u00e1zi vizsg\u00e1lat, <\/strong><\/p>\n

Eur\u00f3pa, 2023. november \u2013 2024. m\u00e1jus<\/strong><\/p>\n

\"\"<\/p>\n

Forr\u00e1s: Antunes L. et al., 20252<\/sup><\/span><\/p>\n

A kutat\u00e1sban azt vizsg\u00e1ltuk, hogy mennyire volt eredm\u00e9nyes a monovalens XBB.1.5 elleni vakcina az \u00fajonnan domin\u00e1nss\u00e1 v\u00e1lt v\u00edrusv\u00e1ltozat okozta s\u00falyos megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9ben. A vizsg\u00e1lati csoport a s\u00falyos akut l\u00e9g\u00fati fert\u0151z\u00e9s miatt k\u00f3rh\u00e1zba ker\u00fclt 65 \u00e9ves vagy id\u0151sebb feln\u0151tt popul\u00e1ci\u00f3 volt.<\/p>\n

Kutat\u00e1sunkban a r\u00e9sztvev\u0151k kiv\u00e1laszt\u00e1sa teszt-negat\u00edv m\u00f3dszerrel t\u00f6rt\u00e9nt, ahol a t\u00fcnetekkel rendelkez\u0151, Rt-PCR teszttel pozit\u00edv eredm\u00e9nyt ad\u00f3 p\u00e1cienseket tekintett\u00fck COVID19 esetnek, a negat\u00edvakat pedig kontrolloknak. Ez a megk\u00f6zel\u00edt\u00e9s lehet\u0151v\u00e9 teszi a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 COVID19-megbeteged\u00e9sek, valamint a kontrollok \u00f6sszehasonl\u00edt\u00e1s\u00e1t.<\/p>\n

Azok k\u00f6z\u00f6tt, akikn\u00e9l az utols\u00f3 COVID19 elleni olt\u00e1s \u00e9s a t\u00fcnetek megjelen\u00e9se k\u00f6z\u00f6tt 14\u201359 nap telt el, a vakcinaeredm\u00e9nyess\u00e9g 45% volt, m\u00edg azokn\u00e1l, akikn\u00e9l 60\u2013119 nap telt el, a becs\u00fclt CVE 34%-nak bizonyult. 4 h\u00f3napon t\u00fal a v\u00e9detts\u00e9g a kimutathat\u00f3s\u00e1g szintje al\u00e1 cs\u00f6kkent.<\/p>\n

2<\/strong>. \u00e1bra: A BA.286\/JN.1 \u00e1ltal domin\u00e1ns id\u0151szakban az XBB.1.5 Covid19 elleni olt\u00f3anyagok eredm\u00e9nyess\u00e9ge a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 SARS-CoV-2 fert\u0151z\u00e9ssel szemben, 65 \u00e9ves \u00e9s id\u0151sebb popul\u00e1ci\u00f3, VE eredm\u00e9nyek – VEBIS k\u00f3rh\u00e1zi vizsg\u00e1lat, Eur\u00f3pa, 2023. november \u2013 2024. m\u00e1jus<\/strong><\/p>\n

\"\"<\/p>\n

Forr\u00e1s: Antunes L. et la., 2025\u2020<\/sup> alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/span><\/p>\n

Az eredm\u00e9nyek r\u00e1mutatnak arra, hogy a 65 \u00e9ves vagy id\u0151sebb betegek k\u00f6r\u00e9ben az olt\u00e1st k\u00f6vet\u0151 els\u0151 4 h\u00f3napban a monovalens, XBB.1.5 COVID19-olt\u00f3anyagok v\u00e9delmet ny\u00fajtottak az \u00fajonnan elterjedt (BA.2.86\/JN.1 lesz\u00e1rmaz\u00e1si vonalba tartoz\u00f3) v\u00edrusvari\u00e1ns \u00e1ltal okozott, k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 COVID19-cel szemben.<\/p>\n

Abstract<\/u><\/strong><\/span><\/p>\n

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86\/JN.1 lineage-predominant period using a multicentre test-negative case\u2013control study in Europe. We included older adults (\u2265\u200965\u2009years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14\u201359\u2009days and 34% at 60\u2013119\u2009days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4\u2009months post-vaccination.<\/p>\n

Antunes, L., Rojas-Castro, M., Lozano, M., Mart\u00ednez-Baz, I., Leroux-Roels, I., Borg, M. L., Oroszi, B., Fitzgerald, M., D\u00fcrrwald, R., Jancoriene, L., Machado, A., Petrovi\u0107, G., Lazar, M., Sou\u010dkov\u00e1, L., Bacci, S., Howard, J., Verdasca, N., Basile, L., Castilla, J., Ternest, S., \u2026 VEBIS SARI VE network team (2025). Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged \u2265\u200965\u2009Years During the BA.2.86\/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza and other respiratory viruses, 19(3), e70081. https:\/\/doi.org\/10.1111\/irv.70081Received: 11 Feb 2025;\u00a0\u00a0 Accepted: 19 Feb 2025<\/span><\/p>\n

https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.70081<\/a><\/p>\n

 <\/p>\n

1.Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n

2. <\/span>Antunes, L., Rojas-Castro, M., Lozano, M., Mart\u00ednez-Baz, I., Leroux-Roels, I., Borg, M. L., Oroszi, B., Fitzgerald, M., D\u00fcrrwald, R., Jancoriene, L., Machado, A., Petrovi\u0107, G., Lazar, M., Sou\u010dkov\u00e1, L., Bacci, S., Howard, J., Verdasca, N., Basile, L., Castilla, J., Ternest, S., \u2026 VEBIS SARI VE network team (2025). Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged \u2265\u200965\u2009Years During the BA.2.86\/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza and other respiratory viruses, 19(3), e70081. https:\/\/doi.org\/10.1111\/irv.70081Received: 11 Feb 2025;\u00a0\u00a0 Accepted: 19 Feb 2025<\/span><\/p>\n

 <\/p>\n

K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

\"\"<\/em>RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n

\"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

A VEBIS1 k\u00f3rh\u00e1zi vizsg\u00e1latba bevont eur\u00f3pai orsz\u00e1gok 65 \u00e9ves \u00e9s id\u0151sebb n\u00e9pess\u00e9ge k\u00f6r\u00e9ben v\u00e9gzett kutat\u00e1s eredm\u00e9nyei, 2023. november \u2013 2024. m\u00e1jus A COVID19 elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9r\u0151l (CVE) egy 12 eur\u00f3pai orsz\u00e1g r\u00e9szv\u00e9tel\u00e9vel zajl\u00f3, multicentrikus k\u00f3rh\u00e1zi vizsg\u00e1latban (VEBIS projekt1) \u00a0v\u00e9gezt\u00fcnk kutat\u00e1st. A kutat\u00e1s id\u0151szak\u00e1ban (2023. november \u00e9s 2024. m\u00e1jus k\u00f6z\u00f6tt) az adapt\u00e1lt monovalens SARS-CoV-2 XBB.1.5 alvari\u00e1ns …<\/p>\n","protected":false},"author":102284,"featured_media":1984,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-1982","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=1982"}],"version-history":[{"count":4,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1982\/revisions"}],"predecessor-version":[{"id":1989,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1982\/revisions\/1989"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/1984"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=1982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=1982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=1982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}